Genova Biopharmaceutical

Genova is a research-driven biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing novel therapeutic protein drugs. The company states that it uses two proprietary technology platforms: one for engineering high-potency protein molecules and another for engineering proteins with prolonged blood half-life. Its disclosed portfolio centers on Novaferon, a novel antiviral and immunomodulatory protein approved for hepatitis B in China and studied for COVID-19, along with long-acting follow-on protein candidates Nova-EPO and Nova-GM-CSF. Genova describes operations spanning research, pilot process development, GMP manufacturing, and regional business activities across North America and Asia. The Japanese entity, Genova Biotech Co., Ltd., is presented as a wholly owned subsidiary of Genova Inc.